Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

(2017) Kevin Fitzgerald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain

(2017) Nathanael G. Lintner et al.   PLOS BIOLOGY

New developments in proprotein convertase subtilisin–kexin 9ʼs biology and clinical implications

(2016) Nabil G. Seidah   CURRENT OPINION IN LIPIDOLOGY

Disrupting the PCSK9/LDLR protein–protein interaction by an imidazole-based minimalist peptidomimetic

(2016) Mattia Stucchi et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor

(2016) Colin W. Garvie et al.   PROTEIN SCIENCE

Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial

(2015) Eveline P. van Poelgeest et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

PCSK9 inhibitors and cardiovascular disease

(2015) M. John Chapman et al.   CURRENT OPINION IN LIPIDOLOGY

Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 In Vitro

(2014) Christina I. Schroeder et al.   CHEMISTRY & BIOLOGY

Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing

(2014) Qiurong Ding et al.   CIRCULATION RESEARCH

Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management

(2014) Gergana Galabova et al.   PLoS One

Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics

(2013) Evan A. Stein et al.   Current Atherosclerosis Reports

Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor

(2013) Yingnan Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels

(2012) Michael T. Lipari et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain

(2012) Yingnan Zhang et al.   JOURNAL OF MOLECULAR BIOLOGY

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

Data processing and analysis with theautoPROCtoolbox

(2011) Clemens Vonrhein et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

REFMAC5 for the refinement of macromolecular crystal structures

(2011) Garib N. Murshudov et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Overview of theCCP4 suite and current developments

(2011) Martyn D. Winn et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

XDS

(2010) Wolfgang Kabsch   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

PHENIX: a comprehensive Python-based system for macromolecular structure solution

(2010) Paul D. Adams et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

The crystal structures of two cuticle-degrading proteases from nematophagous fungi and their contribution to infection against nematodes

(2009) Lianming Liang et al.   FASEB JOURNAL

Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants

(2008) Matthew J. Bottomley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PCSK9: a convertase that coordinates LDL catabolism

(2008) Jay D. Horton et al.   JOURNAL OF LIPID RESEARCH

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA